Skip to main content

Nizatidine Side Effects

Medically reviewed by Last updated on Mar 3, 2024.

Applies to nizatidine: oral capsule, oral tablet.

Serious side effects of Nizatidine

Along with its needed effects, nizatidine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking nizatidine:

More common

Less common


Incidence not known

Other side effects of Nizatidine

Some side effects of nizatidine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common


For Healthcare Professionals

Applies to nizatidine: oral capsule, oral solution, oral tablet.


The most commonly reported side effects included headache, rhinitis, abdominal pain, and diarrhea.[Ref]

Nervous system

A pediatric patient given 2.5 mg/kg orally 2 times a day for 23 days experienced an EEG-diagnosed seizure during treatment.[Ref]

Very common (10% or more): Headache (up to 16.6%)

Common (1% to 10%): Dizziness, somnolence

Frequency not reported: Seizure[Ref]


Common (1% to 10%): Constipation, diarrhea, dry mouth, dyspepsia, flatulence, gastrointestinal disorder, nausea, nausea and vomiting, tooth disorder, vomiting[Ref]


Common (1% to 10%): Cough, cough increased, nasal congestion, nasopharyngitis, pharyngitis, rhinitis, sinusitis

Postmarketing reports: Bronchospasm, laryngeal edema[Ref]


Common (1% to 10%): Accident, asthenia, fever, injury, pain, pyrexia, surgical procedure[Ref]


Common (1% to 10%): Abnormal dreams, anxiety, insomnia, irritability, nervousness

Postmarketing reports: Decreased libido, reversible mental confusion[Ref]


Common (1% to 10%): Pruritus, rash, sweating, urticaria

Postmarketing reports: Exfoliative dermatitis[Ref]


Common (1% to 10%): Back pain, myalgia

Postmarketing reports: Arthralgia[Ref]


Common (1% to 10%): Infection

Rare (0.01% to 0.1%): Serum sickness, serum sickness-like reactions[Ref]


Common (1% to 10%): Chest pain

Frequency not reported: Short episodes of asymptomatic ventricular tachycardia

Postmarketing reports: Vasculitis[Ref]


Common (1% to 10%): Anorexia

Postmarketing reports: Hyperuricemia unrelated to gout or nephrolithiasis[Ref]


Common (1% to 10%): Amblyopia[Ref]


Uncommon (0.1% to 1%): Anemia

Postmarketing reports: Agranulocytosis, eosinophilia, fatal thrombocytopenia, leukopenia, thrombocytopenic purpura[Ref]

Fatal thrombocytopenia was reported in a patient who experienced possible drug-related thrombocytopenia previously received this drug and another histamine-2 (H2) receptor antagonist.[Ref]


Rare (0.01% to 0.1%): Transient, marked transaminase elevations, transient, marked alkaline phosphatase elevations

Frequency not reported: Elevated liver enzyme tests (alkaline phosphatase, ALT, AST), hepatocellular injury, transient, asymptomatic transaminase elevations, transient, asymptomatic alkaline phosphatase elevations

Postmarketing reports: Cholestatic injury, cholestatic injury with jaundice, hepatitis, jaundice, mixed hepatocellular injury, mixed hepatocellular injury with jaundice[Ref]

Some patients developed ALT and/or AST elevations exceeding 500 international units/L, with a report of an ALT level exceeding 2000 international units/L.

Some patients 2 to 18 years developed mild elevations in serum transaminase levels (1 to 2 times the upper limit of normal).

Liver enzyme elevations and liver abnormalities were reversible upon discontinuation of treatment.[Ref]


Postmarketing reports: Anaphylaxis, hypersensitivity reactions[Ref]

Hypersensitivity reactions included bronchospasm, eosinophilia, laryngeal edema, and rash.[Ref]


Postmarketing reports: Impotence[Ref]


Postmarketing reports: Gynecomastia[Ref]


1. Cerner Multum, Inc. Australian Product Information.

2. Product Information. Axid (nizatidine). Lilly, Eli and Company. 2002;PROD.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.